

## Parenteral Formulations of Small Molecules Therapeutics Marketed in the United States (1999) Part II

ROBERT G. STRICKLEY

*Axys Pharmaceuticals, Inc., South San Francisco, California*

[Editor's Note: This review article on Injectable Products is being published in three parts. The introduction and summary appeared in the November/December 1999 issue. The final Part will appear in the March/April 2000 issue of the *Journal*.]










### Injectable Products








#### Sources of Information:









1. Physician's Desk Reference, 53rd ed., Medical Economics Company, Inc., Montvale, NJ, 1999.






Correspondence address: 180 Kimball Way, South San Francisco, CA 94080

2. Lawrence A. Trissel, Handbook on Injectable Drugs, 10th ed., American Society of Health-System Pharmacists, Inc., Bethesda, MD, 1998.
3. Lynn D. Phillips and Merrily A. Kuhn, Manual of IV Medications, 2nd ed., Lippincott-Raven Publishers, Philadelphia, PA, 1999.
4. D. A. Hussar, "New drugs of 1998," *Journal of the American Pharmaceutical Association*, 39, 151 (1999).
5. D. A. Hussar, "New drugs of 1997," *Journal of the American Pharmaceutical Association*, 38, 155 (1998).
6. Food and Drug Administration internet website, <http://www.fda.gov/>, See human drugs, what's new, new and generics approvals.

Drug Name/ Marketed Name	Structure	Formulation	Preadministration preparation	Route of Administration	Company and Indication
Acetazol- amide sodium/ Diamox	 pKa = 7.2	Solution 500 mg pH 9.2	Constitute with 5 mL WFI to ≤ 100 mg/mL.	IV bolus/ IV infusion; IM but may be painful due to alkaline pH	Lederle, Antiglaucoma; diuretic in treatment of mountain sickness
Acyclovir sodium/ Zovirax	 pKa ~ 10	Lyophilized powder 500 - 1000 mg pH 10.5 - 11.6	Reconstitute with WFI to 50 mg/mL; Dilute with dextrose 5% or saline to < 7 mg/mL.	IV infusion over 1 hour	Glaxo Wellcome, Antiviral
Adenosine/ Adenocard IV (bolus), Adenoscan (IV infusion)		Solution 3 mg/mL, Sodium chloride 9 mg/mL, pH 4.5-7.5	None	IV bolus/ IV infusion at 0.14 mg/kg/min for 6 minutes	Fujisawa, Conversion to sinus rhythm of PSVT (bolus). Adjunct for thallium-201 myocardial perfusion scintigraphy (infusion)
Alatrofloxacin mesylate/ Trovan	 Amide prodrug for trovafloxacin	Solution 5 mg/mL pH 3.4-4.3	Dilute with dextrose 5% to 1-2 mg/mL. (potentially incompatible with saline and lactated Ringer's)	IV infusion over 60 minutes	Pfizer, Antibiotic
Alfentanil HCl/ Alfenta		Solution 0.5 mg/mL, Sodium chloride (isotonic) pH 4-6	None for bolus. For IV infusion dilute with saline, dextrose 5%, or lactated Ringer's to 0.025- 0.080 mg/mL.	IV bolus/ IV infusion at 0.5-3.0 ug/kg/min	Taylor, Analgesic
Alprostadil (prostaglan- dinE1/ Caverject		Lyophilized powder 6-46 ug Lactose 172 mg, Sodium citrate 47 mg, Benzyl alcohol 8.4 mg	Reconstitute with 1.2 mL water preserved with benzyl alcohol 0.95% w/v. (~ 0.5-1.1 ug is lost due to adsorption to the vial and syringe.)	Intra- cavernosal	Pharmacia & Upjohn, Erectile dysfunction
Alprostadil alfadex (prosta- glandinE1/ Edex	 complexed with α- cyclodextrin	Lyophilized powder 6-50 ug complexed with 200- 1610 ug of α-cyclodextrin Lactose 56 mg pH 4-8	Reconstitute with 1.2 mL saline.	Intra- cavernosal	Schwarz Pharma, Erectile dysfunction
Amifostine/ Ethiol	 Prodrug that is dephosphorylated by alkaline phosphatase to active free thiol	Lyophilized powder 500 mg	Reconstitute with saline to 50 mg/mL (stable at room temperature for 5 hours). May be further diluted with saline to 5 mg/mL.	IV infusion over 15-30 minutes	Alza, Antineoplastic adjuvant [cytoprotective and radioprotective (reduces toxic effect of cisplatin)]
Amikacin sulfate		Solution 250 mg/mL, Sodium metabisulfite 0.66% Sodium citrate 2.8 % pH 3.5 - 5.5	For IV infusion dilute with saline or dextrose 5% to 2.5-5 mg/mL.	IM/ IV Infusion over 30 - 60 minutes	Elkins-Sinn, Antibiotic

Drug Name/ Marketed Name	Structure	Formulation	Preadministration preparation	Route of Administration	Company and Indication
Aminocaproic acid/ Amicar		Solution 250 mg/mL, Benzyl alcohol 0.9% pH 6.8	Dilute with saline or dextrose 5% to ~ 15- 20 mg/mL.	IV infusion at 4 grams/hour	ImmuneX, Enhancing hemostasis when fibrinolysis contributes to bleeding
Amino- hippurate sodium "PAH"		Solution 200 mg/mL	None	IV infusion at 6-10 mg/kg and 10-24 mg/min	Merck, Measures effective renal plasma flow
Amiodarone HCL/ Cordarone		Solution 50 mg/mL, TWEEN 80 at 10%, Benzyl alcohol 2% pH 4.1	Dilute with dextrose 5% to < 2 mg/mL.	IV infusion at 5-15 mg/min dextrose	Wyeth-Ayerst, Antiarrhythmic, Antianginal
Amitriptyline HCL/ Elavil		Solution 10 mg/mL, Dextrose 44 mg/mL, Methylparaben 1.5 mg/mL, Propylparaben 0.2 mg/mL pH 4-6	None	IM	Zeneca, Antidepressant
Amphotericin B/ Abelcet	 complexed 1:1 (drug-to-lipid molar ratio) with [L- $\alpha$ -dimyristoylphosphatidylcholine (DMPC) and L- $\alpha$ -dimyristoylphosphatidylglycerol (DMPG) in a 7:3 mole ratio]	Liposome opaque suspension 5 mg/mL DMPC 3.4 mg/mL, DMPG 1.5 mg/mL, Sodium chloride 9 mg/mL pH = 5-7	Dilute with dextrose 5% to 1-2 mg/mL.	IV infusion at 2.5 mg/kg/hr	The Liposome Company, Antifungal
Amphotericin B cholesteryl sulfate/ Amphotec	 complexed 1:1 molar with cholesteryl sulfate	Lyophilized powder 50 -100 mg After reconstitution with WFI to a 5 mg/mL colloidal liposomal dispersion, Sodium cholesteryl sulfate 2.6 mg/mL, EDTA 0.037 mg/mL, Lactose 95 mg/mL, TRIS 0.56 mg/mL	Reconstitute with WFI to 5 mg/mL. Dilute with dextrose 5% to 0.16 - 0.83 mg/mL.	IV infusion at 3-4 mg/kg/hr	Sequus (Purchased by AlZA), Antifungal
Amphotericin B/ Ambisome		Lyophilized powder 50 mg After reconstitution with WFI to a 4 mg/mL translucent liposomal suspension, Hydrogenated soy phosphatidylcholine 18 mg/mL, Distearoylphosphatidylglycerol 7 mg/mL, Cholesterol 4 mg/mL, Alpha tocopherol 0.05 mg/mL, Sucrose 75 mg/mL, Disodium succinate 2 mg/mL pH 5.0-6.0	Reconstitute with WFI to 4 mg/mL. Dilute with dextrose 5% to 1-2 mg/mL.	IV infusion at 3-5 mg/kg/hr	Fugisawa (developed by NeXstar, now Gilead), Antifungal

Drug Name/ Marketed Name	Structure	Formulation	Preadministration preparation	Route of Administration	Company and Indication
Ampicillin and Sulbactam sodium/ Unasyn	 Ampicillin Sulbactam	Powder 1-2 grams (ampicillin), 0.5-1.0 grams (sulbactam) pH = 8-10	Reconstitute with WFI to 250 mg/mL ampicillin and 125 mg/mL sulbactam. For IV dilute with saline or dextrose 5% to 3-45 mg/mL.	IM/ IV infusion over 10-30 minutes	Pfizer, Antibacterial (ampicillin)
Amrinone lactate/ Inocor (not in 1999 PDR)		Solution 5 mg/mL, Sodium metabisulfite 0.25 mg/mL, pH = 3-4	None or dilute with saline or half-saline to 1-3 mg/mL.	Slow IV bolus over 2-3 minutes IV infusion at 5-10 ug/kg/min	Sanofi Winthrop, Inotropic and vasodilator (short term management of CHF)
Atenolol/ Tenormin		Solution 0.5 mg/mL, Sodium chloride (to isotonic), Citric acid to pH = 5.5 - 6.2	None, or dilution with saline or dextrose 5%.	IV infusion at 1 mg/min	Zeneca, Antihypertensive and treatment of acute myocardial infarction
Atracurium besylate/ Tracrium		Solution 10 mg/mL w/wo Benzyl alcohol 0.9% pH = 3.2-3.6 (benzene sulfonic acid)	None for IV bolus For IV infusion dilute with saline or dextrose 5% to 0.2- 0.5 mg/mL.	IV bolus/ IV infusion at 5-13 ug/kg/min	Glaxo Wellcome, General anesthesia (Skeletal muscle relaxant)
Atropine sulfate		Solution 0.1-1.0 mg/mL, Sodium chloride 9 mg/mL, w/wo Benzyl alcohol 1.5% pH 3-6	None	SC/ IM/ IV bolus	Elkins-Sinn, Astra, and Baxter, Anticholinergic, Antispasmodic
Aurothio- glucose/ Solganal		Suspension 50 mg/mL in sesame oil Aluminum monostearate 2%, Propylparaben 0.1%	None	IM (oil) Prolonged release due to slow absorption	Schering Corp., Anti-rheumatic
Azathioprine sodium/ Imuran		Lyophilized power 100 mg pH = 9.8-11	Reconstitute with 10 mL WFI. For IV infusion dilute with saline or dextrose 5%.	IV bolus/ IV Infusion	Glaxo Wellcome, Immuno- suppressive anti- metabolite; management of severe rheumatoid arthritis
Azithromy- cin/ Zithromax		Lyophilized powder, 500 mg, Citric acid 414 mg	Reconstitute with 5 mL WFI, and dilute to 1-2 mg/mL with saline, dextrose 5%, or lactated Ringer's.	IV infusion of 500 mg at 1 mg/mL over 3 hours, or 2 mg/mL over 1 hour	Pfizer, Antibiotic

Drug Name/ Marketed Name	Structure	Formulation	Preadministration preparation	Route of Administration	Company and Indication
Aztreonam/ Azactam		1) Lyophilized powder 0.5-2 g, L-arginine 780mg/gram aztreonam pH = 4.5-7.5 2) Frozen Solution 20-40 mg/mL Lactose 14-34 mg/mL, Arginine 16-32 mg/mL pH 4.5-7.5	For IM reconstitute with at least 3 mL WFI or saline to ~ 100-500 mg/mL. For IV bolus reconstitute with WFI to 50-200 mg/mL. For IV infusion reconstitute with 3 mL WFI, then dilute with saline, dextrose 5%, lactated Ringer's to ≤ 20 mg/mL.	IM/ IV bolus/ IV Infusion/	BMS, Antibiotic
Benzquin- amide (Not in 1999 PDR)		Powder 50 mg pH = 3-4	Reconstitute with WFI to 25 mg/mL.	IM/ IV infusion	Pfizer, Prevent nausea with surgery anesthesia
Benztropine mesylate/ Cogentin		Solution 1 mg/mL, Sodium chloride 9 mg/mL pH = 5-8	None	IM/ (IV bolus is alright, but has no advantage over IM)	Merck, Anticholinergic used in psychotic patients with acute dystonic reactions, and in Parkinson's disease
Betametha- sone Phosphate sodium and Betametha- sone Acetate/ Celestone soluspan	 Water soluble phosphate ester prodrug  Water insoluble acetate ester prodrug	Suspension Betamethasone sodium phosphate 3 mg/mL, Betamethasone acetate 3 mg/mL, Sodium phosphate dibasic 7.1 mg/mL, Sodium phosphate monobasic 3.4 mg/mL, EDTA 0.1 mg/mL, Benzalkonium chloride 0.2 mg/mL, pH 6.8-7.2	None	IM	Schering, Anti- inflammatory and for allergies
Bethanechol chloride/ Urecholine		Solution 5.1 mg/mL, pH neutral	None	SC	Merck, Cholinergic

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.